Biogen Inc - BIIB Company Value to Revenue

Public company logo of biogen.com (BIIB)

Biogen Inc. (BIIB) maintains growth supported by stable cash flows from Alzheimer's drug sales, as evidenced by the EV/Sales multiple. High pricing power for unique SMA medications and patent protection against generics establish a solid profit base. The value 4347.21 represents the current metric, capturing the market valuation of the business relative to revenue, excluding debt.

BIIB Biogen Idec: EV/Sales Multiple in the range 11/23/2025 - 11/20/2026

Biogen Idec - analytical breakdowns and key metrics (BIIB)

- share price and consensus valuation forecast:
Fundamental company valuation:biogen.com - BIIB
Original product of Biogen Corp

The EV/Sales metric determines the business value, including net debt, per unit of revenue, allowing for an assessment of the asset's real price regardless of financial leverage. Analyzing the lower bound of the range based on current EV/Sales price action helps investors avoid a "value trap" when seeking an entry point. For Biogen Inc. (BIIB), this indicator reflects the market premium for owning a unique therapeutic ecosystem in the field of neurology.

Competitor analysis

NBIX (Neurocrine Biosciences) - Company Value to Revenue Ratio|RGC: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Axsome (AXSM)|Enterprise Value-to-Revenue Ratio ACADIA Pharmaceuticals Inc|Company Value to Revenue Xenon Pharmaceuticals Inc (XENE)|EV/Sales Multiple VKTX|EV/Sales Multiple supernus.com (SUPN)|Enterprise Value-to-Revenue Ratio Catalyst Pharmaceuticals, Inc. CPRX|DNLI (Denali Therapeutics Inc.) - Enterprise Value to Sales Volume|Harmony Corp - EV/Sales Multiple|BHVN: Enterprise Value-to-Revenue Ratio|AMLX: EV/Sales Multiple|TRVI: Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio Praxis Medicines|Enterprise Value-to-Revenue Multiple Anavex AVXL|Enterprise Value-to-Revenue Ratio CeriBell Corp (CBLL)|Enterprise Value-to-Revenue Coefficient PRTA|EV/Sales Multiple ALEC (Alector)|Annexon (ANNX) - Enterprise Value-to-Revenue Multiple|OMER - Enterprise Value-to-Revenue Ratio|NGNE (Neurogene) - Company Value to Revenue Ratio|ACIU: EV/Sales Multiple|VYGR - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Neumora Therapeutics, Inc.|Company Value to Revenue Ratio SCLX (Scilex)|Company Value to Revenue TVGN (Tevogen Bio)|EV/Sales Multiple Alpha Cognition Inc (ACOG)|EV/Sales Multiple CGTX (cogrx.com)|Total Company Value-to-Revenue Ratio Inhibikase Pharma (IKT)|SAVA: Company Value to Revenue|Total Company Value-to-Revenue Ratio Assertio ASRT|COYA (coyatherapeutics.com) - Company Value to Revenue|Company Value to Revenue Ratio VTGN|OVID (Ovid Therapeutics) - EV/Sales Multiple|Acumen Pharmaceuticals, Inc (ABOS) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio CervoMed, Inc. (CRVO)|ATHE - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple CLNN (Clene Inc.)|Total Company Value-to-Revenue Ratio PepGen Inc. (PEPG)|JUNS - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Relmada Corp|ANVS (Annovis Bio, Inc.) - Company Value to Revenue|Grace Tx (GRCE) - EV/Sales Multiple|Company Value to Revenue AIFF|EV/Sales Multiple anewmeds.com|Enterprise Value-to-Revenue Ratio NeuroSense Therapeutics (NRSN)|RVPH (Reviva Pharmaceuticals Holdings) - Business Value to Revenue|MetaVia - Company Value to Revenue|NRXS: Company Value to Revenue Ratio|Helius Medical Technologies, Inc. - EV/Sales Multiple|PASG: Enterprise Value-to-Revenue Ratio|Neuphoria (NEUP) - Enterprise Value-to-Revenue Ratio|Minerva Neurosciences - Business Value to Revenue|ATHA (Athira Pharma, Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple addextherapeutics.com ADXN|Company Value to Revenue ALZN (Alzamend Neuro Inc.)|CYCN (Cyclerion Therapeutics, Inc.) - Business Value to Revenue|EV/Sales Multiple PTIX (Protagenic)|EV/Sales Multiple pasitheaclinics.com KTTA|CRGT - Enterprise Value-to-Revenue Ratio|Business Value to Revenue ATXI (Avenue Therapeutics)|BCLI: EV/Sales Multiple|Cara Therapeutics - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Chromocell Therapeutics Corporation|EV/Sales Multiple Eliem Therapeutics Inc.|Enterprise Value-to-Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|LBPH (Longboard Pharmaceuticals) - Business Value to Revenue|EV/Sales Multiple MRNS (marinuspharma.com)|NKGN: Company Value to Revenue Ratio|NRBO - Enterprise Value-to-Revenue Ratio|SAGE - EV/Sales Multiple|Synaptogenix (SNPX) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Trevena (TRVN)|Company Value to Revenue VIGL|Company Value to Revenue Ratio WENA (Anew Medical)|EV/Sales Multiple CERE